journal
https://read.qxmd.com/read/38527433/utility-of-echocardiogram-in-neutropenic-patients-with-gram-positive-bacteremia-a-retrospective-study
#1
Neta Sternbach, Haim Ben-Zvi, Ofir Wolach, Moshe Yeshurun, Pia Raanani, Dafna Yahav, Liat Shargian
INTRODUCTION: Hemato-oncology patients are vulnerable to bloodstream infections due to immunocompromised state and use of intravascular catheters. Data regarding risk of infective endocarditis (IE) among those with gram positive bacteremia is limited. We aimed to evaluate the incidence of IE among neutropenic hemato-oncology patients, and to explore the yield of echocardiogram in this population. METHODS: we conducted a single retrospective study of all hospitalized hemato-oncology neutropenic patients with gram positive blood cultures between 2007 and 2021...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38527425/the-ratio-of-serum-urea-nitrogen-to-albumin-is-a-better-predictor-of-os-in-mm-patients-than-urea-nitrogen-alone
#2
JOURNAL ARTICLE
Jiaqi Shao, Enfan Zhang, Haoguang Chen, Zhen Cai, Mengmeng Dong
Introduction Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Abnormally cloned plasma cells secrete large amounts of monoclonal immunoglobulins in the bone marrow of MM patients. Serum urea nitrogen (sUN) is a byproduct of protein metabolism, and its effect on MM patients' prognoses remains unknown. Therefore, we analysed MM patients' clinical data to explore the role of sUN and serum urea nitrogen/serum albumin (sUAR) in the baseline tumor load and MM prognosis of MM patients. Methods We downloaded the clinical data of 762 MM patients from the MMRF database...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38527424/long-non-coding-rna-rp11-252c15-1-is-a-potential-biomarker-of-prognosis-and-hallmark-for-leukemogenesis-in-children-with-b-cell-precursor-acute-lymphoblastic-leukemia
#3
JOURNAL ARTICLE
Lili Pan, Yongzhi Zheng, Hao Zheng
INTRODUCTION: Improved understanding of the prognostic biomarkers associated with childhood acute lymphoblastic leukemia (ALL) is needed for accurate risk group stratification. This study aimed to identify potential long-non coding RNA (lncRNA) markers and evaluate their prognostic value in children with ALL. METHODS: We selected 50 children with newly diagnosed ALL and 20 age-matched patients with idiopathic immune thrombocytopenia (controls). RNA sequencing was performed to identify differentially expressed lncRNAs between the ALL and control groups...
March 25, 2024: Acta Haematologica
https://read.qxmd.com/read/38479365/the-ire1%C3%AE-endonuclease-plays-a-dual-role-in-regulating-the-xbp1-mirna-34a-axis-and-pd-1-expression-within-natural-killer-cells-in-hodgkin-lymphoma
#4
JOURNAL ARTICLE
Karolina Bednarska, Gayathri Thillaiyampalam, Sally Mujaj, Jamie Nourse, Jay Gunawardana, Muhammed B Sabdia, Soi C Law, Anna Pilaar, Qingyan Cui, Lilia M de Long, Frank Vari, Maher K Gandhi, Alexandre S Cristino
INTRODUCTION: Hodgkin Lymphoma (HL) is deficient in Major Histocompatibility Complex-class I, rendering it susceptible to anti-tumoral immunity by Natural Killer (NK)-cells. Despite the functional impairment of PD-1+ NK-cells in HL, the underlying mechanisms of NK-cell dysfunction remain unclear. METHODS: This study involved 14 HL patients and SNK10/KHYG-1 cell lines to assess NK-cell activation against cancer cells. Activation was measured through transcript (PCR) and protein expression (flow cytometry)...
March 13, 2024: Acta Haematologica
https://read.qxmd.com/read/38471491/efficacy-of-preexposure-prophylaxis-with-monoclonal-antibody-tixagevimab-cilgavimab-against-emerging-sars-cov-2-resistant-variants-in-patients-with-chronic-lymphocytic-leukemia
#5
JOURNAL ARTICLE
Ohad Benjamini, Tamar Tadmor, Abraham Avigdor, Rotem Gershon, Limor Kliker, Florin Fares, Nofar Atari, Ilana Laevsky, Bayan Abd Elkader, Tammy Hod, Orit Golan-Shany, Michal Mandelboim, Galia Rahav
Introduction Pre exposure prophylaxis with monoclonal antibodies (mAbs) were developed in addition to COVID19 vaccine for immunocompromised and those with insufficient immune response, among them patients with CLL. Omicron variant and its sublineages evolved mutations that escape mAbs neutralizing effect, yet the extent of which was not studied. Methods We evaluated anti-spike titters and neutralization activity of COVID-19 wild type (WT) , Delta , Omicron, BA2, BA4 and BA5 before and after tixagevimab-cilgavimab (TGM/CGM) dose of 150/150mg or 300/300mg in patients with CLL...
March 12, 2024: Acta Haematologica
https://read.qxmd.com/read/38467116/-momelotinib-bei-myelofibrose-und-an%C3%A3-mie
#6
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 11, 2024: Acta Haematologica
https://read.qxmd.com/read/38461815/the-effect-of-mind-body-intervention-on-lymphocyte-doubling-time-and-treatment-free-survival-in-treatment-na%C3%A3-ve-chronic-lymphocytic-leukemia-patients
#7
JOURNAL ARTICLE
Shirley Shapira, Naama Hirschberger, Yishai Ofran, Barak Mizrahi, Esti Mandel, Ohad Benjamini, Noa Rabinowicz, Adi Zoref-Lorenz
INTRODUCTION: Mind-Body Intervention (MBI) serves as supportive aid in oncology. We hypothesized that MBI could impact the progression of Chronic Lymphocytic Leukemia (CLL) in the 'watch and wait' (w&w) phase. METHODS: MBI was utilized in a non-randomized prospective controlled study between 02/2020-02/2022 in 76 treatment-naïve CLL patients in the w&w phase (37 intervention and 39 control patients). The primary and secondary endpoints were prolongation of Lymphocyte Doubling Time (LDT) and treatment-free survival (TFS)...
March 8, 2024: Acta Haematologica
https://read.qxmd.com/read/38447541/peeling-back-the-layers-recurrent-talquetamab-skin-toxicity-after-supportive-stem-cell-boost-in-multiple-myeloma
#8
Alexander D Heini, Vera Ulrike Bacher, Dilara Akhoundova, Katja Seipel, Thomas Pabst
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on multiple myeloma plasma cells as well as in keratinized tissues. Due to the expression pattern, toxicity of talquetamab involves skin toxicity. Here we report the case of a patient who was treated with talquetamab after relapse after CAR-T therapy. The patient developed a severe recurrence of talquetamab-mediated skin toxicity after the administration of a supportive hematopoietic stem cell boost to treat persistent late cytopenias after CAR-T therapy...
March 6, 2024: Acta Haematologica
https://read.qxmd.com/read/38432198/primary-nodal-epstein-barr-virus-positive-t-cell-nk-cell-lymphoma-real-world-experience
#9
JOURNAL ARTICLE
Dae-Ho Choi, Sang Eun Yoon, Junhun Cho, Seok Jin Kim, Won Seog Kim
PTCL-EBV is a disease entity newly recognized in the WHO-HAEMS5 and the ICC of Mature Lymphoid neoplasms classification. Previously, it was classified as a subtype within PTCL-NOS and was known to have a poor prognosis. However, the clinical feature and treatment outcomes are not well known. This retrospective observational study was conducted on patients diagnosed with PTCL-EBV at Samsung Medical Center through a pathology review from 2000 to 2020. We analyzed clinical data from 14 patients. We conducted an investigation of patients with PTCL-EBV into immunohistochemistry and analysis of survival outcomes for each treatment regimen...
March 3, 2024: Acta Haematologica
https://read.qxmd.com/read/38432204/venous-thromboembolism-prophylaxis-in-inflammatory-bowel-disease-inpatients-systematic-review-and-meta-analysis
#10
Rotem McNeil, Danielle Fredman, Ofir Eldar, Anat Gafter-Gvili, Tomer Avni
INTRODUCTION: Inflammatory bowel disease (IBD) patients are three-times more likely to develop venous thromboembolism (VTE), and guidelines recommend prophylaxis during all hospitalizations. In this systematic review we sought to assess for the benefits and risks of VTE prophylaxis in hospitalized IBD patients. METHODS: We performed a systematic review and meta-analysis. We searched MEDLINE and others up to 2/2022, for studies on IBD inpatients treated with prophylactic anti-coagulation during hospitalization, compared to no prophylaxis...
March 1, 2024: Acta Haematologica
https://read.qxmd.com/read/38432202/impacts-of-posttransplant-cyclophosphamide-dose-on-graft-versus-leukemia-effects-via-hla-b-leader-in-hla-haploidentical-peripheral-blood-stem-cell-transplantation
#11
Makoto Moriguchi, Kentaro Ido, Hiroshi Okamura, Mika Nakamae, Kazuki Sakatoku, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Asao Hirose, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
INTRODUCTION: The graft-versus-leukemia effect of HLA-B leader dimorphism, i.e. methionine (M) or threonine (T) at position -21 of the leader sequence, has been observed in HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo). However, the biological mechanism has been unclear, and the contributions of HLA-B leader genotype to risk reduction of relapse might be dependent on posttransplant cyclophosphamide (PTCy) doses. METHODS: To investigate whether the effect of HLA-B leader dimorphism was modified by the PTCy dose, we retrospectively analyzed 99 patients who received PTCy-haplo...
March 1, 2024: Acta Haematologica
https://read.qxmd.com/read/38417413/impact-of-covid-19-on-patients-with-beta-thalassemia-major-an-observational-study
#12
JOURNAL ARTICLE
Nadia Vacca, Cristian Locci, Fabiola Serra, Elena Chicconi, Mariangela V Puci, Giovanni Sotgiu, Antonio Matteo Amadu, Roberto Antonucci
INTRODUCTION:  The prevalence of COVID-19 is slightly lower, and its mortality is higher in beta-thalassemia patients than in the general population. We evaluated the impact of COVID-19 in terms of incidence, clinical course, management, and specific antibody response to vaccination in a cohort of patients with beta-thalassemia major. METHODS:  We retrospectively enrolled all transfusion-dependent beta-thalassemia major patients attending the Thalassemia Day Care Center of the University Hospital of Sassari, Italy, from March 1, 2020, to May 31, 2021...
February 28, 2024: Acta Haematologica
https://read.qxmd.com/read/38412838/erratum
#13
(no author information available yet)
No abstract text is available yet for this article.
February 27, 2024: Acta Haematologica
https://read.qxmd.com/read/38408440/zanubrutinib-plus-cytarabine-in-patients-with-refractory-relapsed-primary-central-nervous-system-lymphoma
#14
JOURNAL ARTICLE
Zhiguang Lin, Jingjing Ma, Yan Ma, Qing Li, Hui Kang, Mengxue Zhang, Bobin Chen
INTRODUCTION: Primary central nervous system lymphoma (PCNSL) is a rare subtype of aggressive extranodal non-Hodgkin lymphoma. Currently, there is no standard of care for the treatment of refractory or relapsed PCNSL (r/r PCNSL). We conducted a prospective single-arm phase II study to evaluate zanubrutinib plus cytarabine for r/r PCNSL. METHODS: Using Simon's two-stage design, we analyzed 34 patients who received high-dose cytarabine (3.0 g/m2 once daily) for 2 days and zanubrutinib (160 mg twice daily) for 21 days each cycle for up to 6 cycles...
February 26, 2024: Acta Haematologica
https://read.qxmd.com/read/38402867/oncogenic-mtor-signaling-axis-compensates-btk-inhibition-in-a-chronic-lymphocytic-leukemia-patient-with-richter-transformation-a-case-report-and-review-of-the-literature
#15
Thomas Parigger, Stephan Drothler, Christian Scherhäufl, Franz Josef Gassner, Maria Schubert, Markus Steiner, Jan Philip Höpner, Alexandra Hödlmoser, Lena Schultheis, Aryunni Abu Bakar, Daniel Neureiter, Lisa Pleyer, Alexander Egle, Richard Greil, Roland Geisberger, Nadja Zaborsky
INTRODUCTION: Targeting the B cell receptor (BCR) pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates...
February 24, 2024: Acta Haematologica
https://read.qxmd.com/read/38382483/evaluating-the-economic-burden-of-acute-myeloid-leukemia-in-canada
#16
JOURNAL ARTICLE
Jean Lachaine, Catherine Beauchemin, Fatéma Dodat, Yunghan Au, William K Evans, Brian Leber, Kristjan Paulson, Andre Schuh, John Storring
Background Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated the total cost of illness associated with newly diagnosed AML patients in Canada. Methods The economic burden of AML was estimated using an incidence-based model, analyzing different types of AML cases in Canada. Direct and indirect costs were calculated using scientific literature and Canadian clinical experts' inputs. Patients were categorized depending on their eligibility for intensive chemotherapy (fit and unfit patients) as well as according to age and cytogenetic markers...
February 21, 2024: Acta Haematologica
https://read.qxmd.com/read/38368853/clinical-outcomes-survival-and-predictors-in-lower-risk-myelodysplastic-syndrome-patients-treated-with-cyclosporine-a
#17
JOURNAL ARTICLE
Yingjia Lu, Lina Zhang, Weiying Qu, Zhou Feng, Yuan Deng, Lin Zhao
INTRODUCTION: Therapeutic options to improve myelodysplastic syndrome (MDS)-related cytopenias in patients with lower-risk MDS are limited, and cyclosporin A (CSA) is an available option. METHODS: We retrospectively analysed the clinical data of 153 consecutive patients with lower-risk MDS at our institution from July 1997 to October 2017. Propensity score matching method was used to balance the influence of confounding factors between patients with MDS treated with CSA and other conventional treatments (excluding CSA), and 50 pairs of cases were successfully identified for the final analysis...
February 17, 2024: Acta Haematologica
https://read.qxmd.com/read/38359808/acquired-von-willebrand-syndrome-associated-with-a-smoldering-multiple-myeloma-successfully-treated-by-daratumumab-lenalidomide-and-dexamethasone
#18
Michael Iarossi, Marie-Christiane Madeleine Vekemans, Nicolas Weynants, Cedric Hermans
INTRODUCTION: Acquired von Willebrand syndrome (AvWS) is a rare entity with approximately 700 cases described in the literature. A number of etiologies are responsible for this condition, mainly lymphoproliferative, myeloproliferative syndromes and cardiac diseases. Management is aimed at preventing and treating bleeds, as well as treating the underlying pathology. In the case of a monoclonal gammopathy, there is limited evidence and high heterogeneity only based on old case reports, resulting in poor quality recommendations...
February 15, 2024: Acta Haematologica
https://read.qxmd.com/read/38359806/persistent-covid-19-a-case-report-of-an-immunocompromised-patient-and-a-literature-review
#19
Sirine Bekkaoui, Geoffroy Venton, Fannie Bretelle, Victoria Garrido, Victor Chabbert, Stéphane Gayet, Paul Dalmas, Antoine Tichadou, Pierre-André Jarrot, Patrick Villani, Aurélie Daumas, Robin Arcani
Introduction Immunocompromised patients can show prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and persistent symptoms, which is called persistent COVID-19. Case presentation We report a case of an immunocompromised patient who was treated for mantle cell lymphoma and was suffering from B-cell depletion. The patient developed persistent COVID-19, which was confirmed by real-time polymerase chain reaction (RT-PCR) tests in only sputum and bronchoalveolar fluid which remained positive for at least 112 days...
February 15, 2024: Acta Haematologica
https://read.qxmd.com/read/38359803/lenalidomide-treatment-of-isolated-central-nervous-system-relapse-in-acute-lymphoblastic-leukemia-after-hsct-and-car-t-cell-therapy
#20
Qing Zhang, Yi Dong, Zhimin Zhai, Lili Tao, Qianshan Tao
INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell are effective treatments for acute lymphoblastic leukemia (ALL). Various forms of intra- and extra-medullary relapses have been reported after HSCT and CAR-T cell therapy for ALL; however, no reports have investigated isolated central nervous system (CNS) relapse after HSCT and CAR-T cell therapy. Hence, no clinical treatment has been established for such rare patients. CASE PRESENTATION: An 18-year-old male patient with B cell ALL suffered from isolated CNS relapse after HSCT and CAR-T cell therapy...
February 15, 2024: Acta Haematologica
journal
journal
21868
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.